TSPO imaging-guided characterization of the immunosuppressive myeloid tumor microenvironment in patients with malignant glioma.
DPA-714
GAMs
MDSCs
PET
TAMs
TSPO
glioma
imaging biomarker
tumor microenvironment
Journal
Neuro-oncology
ISSN: 1523-5866
Titre abrégé: Neuro Oncol
Pays: England
ID NLM: 100887420
Informations de publication
Date de publication:
07 07 2020
07 07 2020
Historique:
pubmed:
13
2
2020
medline:
10
4
2021
entrez:
13
2
2020
Statut:
ppublish
Résumé
Tumor-associated microglia and macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) are potent immunosuppressors in the glioma tumor microenvironment (TME). Their infiltration is associated with tumor grade, progression, and therapy resistance. Specific tools for image-guided analysis of spatiotemporal changes in the immunosuppressive myeloid tumor compartments are missing. We aimed (i) to evaluate the role of fluorodeoxyglucose (18F)DPA-714* (translocator protein [TSPO]) PET-MRI in the assessment of the immunosuppressive TME in glioma patients, and (ii) to cross-correlate imaging findings with in-depth immunophenotyping. To characterize the glioma TME, a mixed collective of 9 glioma patients underwent [18F]DPA-714-PET-MRI in addition to [18F]fluoro-ethyl-tyrosine (FET)-PET-MRI. Image-guided biopsy samples were immunophenotyped by multiparametric flow cytometry and immunohistochemistry. In vitro autoradiography was performed for image validation and assessment of tracer binding specificity. We found a strong relationship (r = 0.84, P = 0.009) between the [18F]DPA-714 uptake and the number and activation level of glioma-associated myeloid cells (GAMs). TSPO expression was mainly restricted to human leukocyte antigen D related-positive (HLA-DR+) activated GAMs, particularly to tumor-infiltrating HLA-DR+ MDSCs and TAMs. [18F]DPA-714-positive tissue volumes exceeded [18F]FET-positive volumes and showed a differential spatial distribution. [18F]DPA-714-PET may be used to non-invasively image the glioma-associated immunosuppressive TME in vivo. This imaging paradigm may also help to characterize the heterogeneity of the glioma TME with respect to the degree of myeloid cell infiltration at various disease stages. [18F]DPA-714 may also facilitate the development of new image-guided therapies targeting the myeloid-derived TME.
Sections du résumé
BACKGROUND
Tumor-associated microglia and macrophages (TAMs) and myeloid-derived suppressor cells (MDSCs) are potent immunosuppressors in the glioma tumor microenvironment (TME). Their infiltration is associated with tumor grade, progression, and therapy resistance. Specific tools for image-guided analysis of spatiotemporal changes in the immunosuppressive myeloid tumor compartments are missing. We aimed (i) to evaluate the role of fluorodeoxyglucose (18F)DPA-714* (translocator protein [TSPO]) PET-MRI in the assessment of the immunosuppressive TME in glioma patients, and (ii) to cross-correlate imaging findings with in-depth immunophenotyping.
METHODS
To characterize the glioma TME, a mixed collective of 9 glioma patients underwent [18F]DPA-714-PET-MRI in addition to [18F]fluoro-ethyl-tyrosine (FET)-PET-MRI. Image-guided biopsy samples were immunophenotyped by multiparametric flow cytometry and immunohistochemistry. In vitro autoradiography was performed for image validation and assessment of tracer binding specificity.
RESULTS
We found a strong relationship (r = 0.84, P = 0.009) between the [18F]DPA-714 uptake and the number and activation level of glioma-associated myeloid cells (GAMs). TSPO expression was mainly restricted to human leukocyte antigen D related-positive (HLA-DR+) activated GAMs, particularly to tumor-infiltrating HLA-DR+ MDSCs and TAMs. [18F]DPA-714-positive tissue volumes exceeded [18F]FET-positive volumes and showed a differential spatial distribution.
CONCLUSION
[18F]DPA-714-PET may be used to non-invasively image the glioma-associated immunosuppressive TME in vivo. This imaging paradigm may also help to characterize the heterogeneity of the glioma TME with respect to the degree of myeloid cell infiltration at various disease stages. [18F]DPA-714 may also facilitate the development of new image-guided therapies targeting the myeloid-derived TME.
Identifiants
pubmed: 32047908
pii: 5734268
doi: 10.1093/neuonc/noaa023
pmc: PMC7339888
doi:
Substances chimiques
Fluorine Radioisotopes
0
Receptors, GABA
0
TSPO protein, human
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1030-1043Informations de copyright
© The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
J Nucl Med. 2015 Jul;56(7):1048-54
pubmed: 26025960
Curr Opin Neurol. 2018 Dec;31(6):720-726
pubmed: 30239359
J Nucl Med. 2015 Apr;56(4):512-7
pubmed: 25722450
J Nucl Med. 2013 Dec;54(12):2125-31
pubmed: 24212976
Clin Cancer Res. 2013 Jun 15;19(12):3165-75
pubmed: 23613317
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):540-557
pubmed: 30519867
Theranostics. 2018 Apr 3;8(10):2603-2620
pubmed: 29774062
J Cereb Blood Flow Metab. 2015 Nov;35(11):1711-21
pubmed: 26126867
Neurosurgery. 2019 Dec 1;85(6):E1020-E1029
pubmed: 31215632
Biochem Pharmacol. 2004 Aug 15;68(4):689-98
pubmed: 15276076
Eur J Nucl Med Mol Imaging. 2019 Mar;46(3):580-590
pubmed: 30244386
Genome Biol. 2017 Dec 20;18(1):234
pubmed: 29262845
Cancer Res. 1995 Jun 15;55(12):2691-5
pubmed: 7780986
Immunotherapy. 2018 Feb 1;10(4):317-339
pubmed: 29421984
Neuro Oncol. 2016 Sep;18(9):1199-208
pubmed: 27106405
Eur J Nucl Med Mol Imaging. 2015 Mar;42(3):478-94
pubmed: 25488184
Theranostics. 2017 Jan 6;7(2):493-512
pubmed: 28255345
Neuro Oncol. 2016 Sep;18(9):1253-64
pubmed: 27006175
Theranostics. 2019 Feb 20;9(6):1523-1537
pubmed: 31037121
Neuro Oncol. 2016 Jun;18(6):807-18
pubmed: 26578623
Int J Cancer. 2007 Jul 1;121(1):95-105
pubmed: 17315190
Mol Imaging. 2017 Jan 1;16:1536012116687651
pubmed: 28654379
J Neurooncol. 2019 Jan;141(1):83-94
pubmed: 30506500
J Nucl Med. 2015 Sep;56(9):1386-90
pubmed: 26182972
Lancet Oncol. 2009 May;10(5):459-66
pubmed: 19269895
Genome Biol. 2017 Dec 21;18(1):235
pubmed: 29262851
Cancer Cell. 2017 Mar 13;31(3):326-341
pubmed: 28292436
J Immunother Cancer. 2019 Feb 27;7(1):58
pubmed: 30813960
JCI Insight. 2016;1(2):
pubmed: 26973881
Neuro Oncol. 2019 Jun 10;21(6):755-764
pubmed: 30721979
Appl Radiat Isot. 2012 Mar;70(3):489-97
pubmed: 22104496
Eur J Nucl Med Mol Imaging. 2012 May;39(5):811-23
pubmed: 22270507
Eur J Nucl Med Mol Imaging. 2017 Dec;44(13):2230-2238
pubmed: 28821920
J Nucl Med. 2005 Mar;46(3):411-6
pubmed: 15750152
Lancet. 2019 Feb 16;393(10172):678-688
pubmed: 30782343
J Nucl Med. 2008 May;49(5):814-22
pubmed: 18413395
Neuro Oncol. 2009 Aug;11(4):394-402
pubmed: 19028999
Nat Immunol. 2018 Feb;19(2):108-119
pubmed: 29348500
Nat Neurosci. 2016 Jan;19(1):20-7
pubmed: 26713745
J Neurooncol. 2007 Jan;81(1):1-7
pubmed: 16868661
Cancer Res. 2017 Apr 15;77(8):1831-1841
pubmed: 28137769
Acta Neuropathol. 2016 Jun;131(6):803-20
pubmed: 27157931